Resultados de la búsqueda 271-280 of 15528 for LL-37
... 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated ... (2-4) advanced, unresectable breast cancer (up to 6 donors per phenotype ...
This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer.
... (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated calreticulin (muCALR); (3) Cohort 3 focuses on glioblastoma multiforme ...
Accessed March 2, 2025. Kobayashi S, et al Analysis of adverse events of cholinesterase inhibitors and NMDA receptor antagonists on arrhythmias using the ...
... 2-6: 500 mg/m2). Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) ...
Phase 2 Trial Of Voyager V1 In Combination With Cemiplimab In Cancer Patients ... (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) displaying ...
Part 2: According to the 2022 Center for CDC guidelines for Hepatitis B vaccination in immunocompromised adults, persons found to have antibody titer ...
... 2 genes (BRCA 1/2) and PALB2 associated HER2-negative metastatic breast cancer. The names of the study drugs involved in this study are: * Axatilimab (a ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?